FirstHealth of the Carolinas

Clinical Trial Details

Study Title: GOG 237: Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Study Type: Interventional
Study Condition: Cervical Cancer
Investigator: Dr. John Byron
Phone: (910) 692-7928
Research Coordinator: Pam Mason
Phone: (910) 715-2200
Eligibility Criteria: Women, ages 18 years or older, with confirmed atypical glandular cells (AGC) of the cervix. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Gynecologic Oncology Group
Study Rationale: Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.
Study Purpose: This clinical trial is studying biomarkers in diagnosing cervical lesions in patients with abnormal cervical cells.
Study Link:
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.